mCig, Inc. - Forms Medical Advisory Board in Preparation for Next Line of Products
January 22 2014 - 8:30AM
mCig, Inc. (OTCQB:MCIG) is pleased to announce the formation of a
Medical Advisory Board to help oversee the company's strategy and
assist in the preparation to enter new markets. The first addition
to the board is Dr. Khary Bryan, the official representative of
Cannatest in the New England States.
Dr. Khary Bryan Biography:
Dr. Khary Bryan is a 2001 graduate of the Philadelphia College
of Pharmacy. During the six years of Doctor of Pharmacy training,
his personal goal was to learn different methods of disease
prevention in addition to the pharmaceutical management of disease.
It was during this time he discovered the role of nutraceuticals
and functional foods in the prevention and treatment of disease,
although his parents exposed him to herbal medicine and a disease
prevention lifestyle from an early age. In 2010 Dr. Bryan became
aware of the endocannabinoid system and began to attend cannabis
industry conferences in order to gain more knowledge. In 2011
he established a relationship with the cannabinoid analysis
company Cannatest and in 2012 began to represent Cannatest in the
medical cannabis of New England States. In this role he
educates legal caregivers and patients about the science of the
endocannabinoid system, cannabis plant, and High Performance Thin
Layer Chromatography cannabinoid analysis method. Dr. Bryan
also works as a community pharmacist in Connecticut and is a member
of the International Cannabinoid Research Society, Canadian
Consortium for the investigation of Cannabinoids and the Society of
Cannabis Clinicians.
Commenting on his appointment Dr. Bryan stated: "I am eager to
lead the mCig Medical Advisory Board and contribute to the
momentum of the company through the continued enhancement of
vaporization efficiency. Additionally, I envision the mCig
device as a delivery method for therapeutic plant secondary
metabolite vapor and will be working toward this goal."
The company has previously stated it is developing a new product
codenamed: "VITA". The company expects to update its shareholders
on the progress of this new division in the coming weeks. This
product will provide entry into a totally new market for mCig,
Inc.
Non-Dilutive Transaction
As part of this transaction Mr. Paul Rosenberg mCig CEO has
committed to cancel an equal amount of his shares against any
shares issued to Dr. Khary Bryan.
About mCig, Inc. mCig, Inc. (OTCQB:MCIG) is a technology company
focused on two long-term secular trends sweeping the globe: (1) The
decriminalization and legalization of marijuana for medicinal or
recreational purposes (2) The adoption of electronic vaporizing
cigarettes (commonly known as "eCigs") by the world's 1.2 Billion
smokers. The company manufactures and retails the mCig – a purpose
built loose leaf eCig retailing at only $10. Designed in the USA –
the mCig provides a superior smoking experience by heating plant
material, waxes, and oils delivering a smoother inhalation
experience. See more at: http://www.mcig.org/ The company believes
that a well regulated marijuana industry is emerging as more states
follow the lead of Washington and Colorado in legalizing marijuana.
A similar trend is developing within the eCig industry following
the first acquisition of an electronic cigarette brand (Blucigs) by
a traditional tobacco company Lorillard Inc. for $135 million.
Wells Fargo analyst Bonnie Herzog estimates that eCig sales may
rise from $1 Billion in 2013 to $10 billion over the next three
years. mCig, Inc. (OTCQB:MCIG) has positioned itself as a first
mover at the intersection of these two trends and hopes to create
shareholder value by making the mCig one of the leading choices for
electronic consumption of plant material. - See more at:
http://www.mcig.org/investors/investor-opportunity-subpage/ Safe
Harbor Statement Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but
are subject to a number of risks and uncertainties. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products based on its technology; the expected benefits
and efficacy of the Company's products and technology; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
and future product commercialization; and the Company's business,
research, product development, regulatory approval, marketing and
distribution plans and strategies.
CONTACT: Paul Rosenberg
CEO
(425)462-4219